- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00732173
Exercise and Healthy Diet or Standard Care in Patients in Remission From Stage I or Stage II Endometrial Cancer
Survivors of Uterine Cancer Empowered By Exercise and Healthy Diet (SUCCEED)
RATIONALE: Participating in a diet and exercise program may improve the quality of life of overweight and obese patients who are in remission from endometrial cancer.
PURPOSE: This randomized phase I trial is studying an exercise and healthy diet program to see how well it works compared with standard care in patients in remission from stage I or stage II endometrial cancer.
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVE:
* To reduce morbidity and early mortality in endometrial cancer (EC) survivors through obesity management.
SECONDARY OBJECTIVES:
- To expand and refine a previous pilot study of a behavioral, lifestyle-change education intervention for use in overweight and obese patients in remission from endometrial carcinoma.
- To determine the potential effects and variation of each regimen in these patients.
- To explore potential mediators (self-efficacy, depression) and moderators (body mass index) of healthful dietary and exercise behaviors.
- To evaluate neuronal response to high-versus-low calorie visual food stimuli under fasted (hunger) and fed (satiated) states in brain regions of interest (hypothalamus, lateral orbitofrontal cortex, ventral striatum, insula) using blood oxygenation level dependent (BOLD) functional magnetic resonance imaging (fMRI) before and after a lifestyle (diet and exercise counseling) intervention or usual care in obese EC patients. We will also compare the neuronal responses in obese EC patients to those from normal weight subjects without cancer being seen at the same gynecologic clinic; and, explore modification of the neuronal signals by candidate genes and serum biomarkers in the hypothalamic pituitary-adrenal axis, serotonergic and inflammatory pathways.
OUTLINE: Patients are stratified according to body mass index (25.0-39.9 vs ≥ 40) and randomized to 1 of 2 intervention arms.
- Arm I: Patients receive a lifestyle intervention, "Survivors of Uterine Cancer Empowered by Exercise and Healthy Diet (SUCCEED)", on a group and individual basis consisting of nutrition, exercise, and behavioral modification counseling from a physician, psychologist, registered dietitian, and physical therapist. Sixteen group sessions will be conducted (10 weekly, 6 bi-weekly) for 6 months. Weight and body mass index, satisfaction with study treatment, and exercise/activity logs are assessed weekly and biweekly. Patients receive additional feedback and support during the weeks not met in a group, including newsletters and telephone and e-mail contact.
- Arm II (control): Patients receive usual care informational brochures, but no lifestyle counseling, related to weight loss, physical activity, and nutrition.
Patients undergo physician counseling sessions at baseline and 3, 6, and 12 months. Patients are assessed by weight, anthropometric measures, and body mass index; biomarkers; body composition by dual-energy x-ray absorptiometry/densitometry (DEXA); co-morbidities by the Charlson co-morbidity score; depression by the Beck Depression Inventory (BDI); eating patterns by the Three-Factor Eating Inventory (EI); exercise/physical activity by Leisure Score Index (LSI) and pedometer step count; nutrient intake by 24-hour recall; quality of life by the Functional Assessment of Cancer Therapy-General (FACT-G) and Short-form Medical Outcomes (SF-36); and self-efficacy by the Self-Efficacy Questionnaire (SEQ) and the Weight Efficacy Life-Style (WEL).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44106-5065
- Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed stage I or II (early) endometrial carcinoma
- Diagnosed within the past 3 years
Underwent prior surgery consisting of a total abdominal hysterectomy and bilateral salpingo-oophorectomy
- No evidence of disease
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- BMI ≥ 25 (overweight/obese)
- Medical clearance from primary care physician
- Approved for contact by treating gynecologic oncologist
- At least a 6th-grade reading level to complete significant reading and homework
- No severe psychiatric illness (e.g., schizophrenia, bipolar disorder) or major depression (Beck Depression Inventory > 29) that needs more aggressive, problem-focused interventions
- No dementia or cognitive deficits
- No pre-existing medical conditions that would be a barrier for participation in unsupervised walking
- No participation in a structured weight loss or exercise program in the past 6 months
- Must agree to and be available for longitudinal follow-up assessments
- Non-English speakers may bring an English-speaking person to all group sessions and visits
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm I
Patients receive a lifestyle intervention, "Survivors of Uterine Cancer Empowered by Exercise and Healthy Diet (SUCCEED)", on a group and individual basis consisting of nutrition, exercise, and behavioral modification counseling from a physician, psychologist, registered dietitian, and physical therapist.
Sixteen group sessions will be conducted (10 weekly, 6 bi-weekly) for 6 months.
Weight and body mass index, satisfaction with study treatment, and exercise/activity logs are assessed weekly and biweekly.
Patients receive additional feedback and support during the weeks not met in a group, including newsletters and telephone and e-mail contact.
|
Undergo SUCCEED lifestyle intervention
Undergo SUCCEED lifestyle intervention
Undergo SUCCEED lifestyle intervention
Receive information
Undergo SUCCEED lifestyle intervention
|
|
Active Comparator: Arm II
Patients receive usual care informational brochures but no lifestyle counseling related to weight loss, physical activity, and nutrition.
|
Receive information
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Weight change
Time Frame: at baseline and 3, 6, and 12 months.
|
Analysis will be carried out by fitting a mixed model.
Weight change will be expressed in terms of absolute and relative weight change.
In addition, percent weight change will be calculated.
To test the null hypotheses that the groups do not differ in terms of change in weight at 6 or 12 months, parameter estimates from the model will be used to construct subsequent t-test that the difference in means at 3, 6, or 12 months is zero.
|
at baseline and 3, 6, and 12 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quantitative and qualitative nutrient intake
Time Frame: at baseline and 3, 6, and 12 months.
|
24 hour dietary recalls will be conducted using the United States Department of Agriculture (USDA) 5 Step Multiple Pass Method.
Information about dietary supplement use will also be obtained.
Food intake will be entered into Nutritionist Pro.
Fruit/vegetable intake will be assessed using the National Cancer Institute (NCI) All-Day Fruit and Vegetable Screener, which has 10 questions which assess intake of fruits and vegetables during the previous month.
A mixed modeling approach will be used.
|
at baseline and 3, 6, and 12 months.
|
|
Minutes spent in moderate and vigorous physical activity
Time Frame: at baseline and 3, 6, and 12 months.
|
Assessed with the validated Godin Leisure-Time Exercise questionnaire, a four-item query of usual leisure-time exercise habits.
Average frequency of milk, moderate, and strenuous exercise during a typical week are assessed.
Duration in minutes of activity along with specific questions regarding walking are included.
Complete 7-day pedometer step test at baseline and at 6 and 12 months.
A mixed modeling approach will be used.
|
at baseline and 3, 6, and 12 months.
|
|
Body composition, using dual energy x-ray absorptiometry/densitometry (DEXA) methodology
Time Frame: at baseline and 3, 6, and 12 months.
|
Measured in a random subsample.
Lean body mass, body fat composition, and bone mineral density will be measured.
Body composition will be analyzed to determine changes along with weight to help track effectiveness of the intervention.
|
at baseline and 3, 6, and 12 months.
|
|
Biomarkers for metabolic syndrome and nutrition
Time Frame: at baseline and 3, 6, and 12 months.
|
Serum biomarkers analyzed for changes along with weight to help track effectiveness of the intervention.
Risk factors of metabolic syndrome: low density lipoprotein (LDL), high density lipoprotein (HDL), serum triglycerides, and fasting glucose.
Plasma carotenoids (alpha-carotene, beta-carotene, lutein, zeaxanthin) and lycopene concentrations for changes in fruit and vegetable intake.
Sub-Study, serum for appetite-related hormones and inflammatory cytokines: leptin, insulin, adiponectin, resistin, IGF-1, IGFBP-1, IGFBP-3, IL-6, TNF-α, MCP-1, glucagon, GLP-1 active, and thyroid hormones.
|
at baseline and 3, 6, and 12 months.
|
|
Self-efficacy
Time Frame: at baseline and 3, 6, and 12 months.
|
Self-Efficacy Questionnaire: Physical Activities, an 8 item measure of respondents' perception of the degree to which they feel able to make changes in their physical activity level.
Weight Efficacy Life-Style (WEL) questionnaire, 20 questions in 5 situational factors, where subjects rate their ability to successfully resist the desire to eat using a 10-point scale.
Methodology of Baron and Kenny used to test for mediating effect of self-efficacy.
Multiple regression analyses used to provide statistical tests of the possible mediating role of self-efficacy.
|
at baseline and 3, 6, and 12 months.
|
|
Depression
Time Frame: at baseline and 3, 6, and 12 months.
|
Assessed using the Beck Depression Inventory (BDI), a 21-item, Likert-scaled instrument of depressive symptoms.
Methodology of Baron and Kenny used to test for mediating effect of depression.
Multiple regression analyses used to provide statistical tests of the possible mediating role of depression.
|
at baseline and 3, 6, and 12 months.
|
|
Quality of life
Time Frame: at baseline and 3, 6, and 12 months.
|
Using Functional Assessment of Cancer Therapy-General (FACT-G), a 27-item core questionnaire evaluating various domains of QOL including physical, functional, family-social, and emotional well-being with questions answered on a 5-point Likert scale and items summated to give scores for each domain; a 13-item fatigue subscale; and the FACT-Endometrial (En), a 16-item subscale specific for EC.
Also using Short-Form (SF)-36, with 36 questions scored on a Likert scale, producing overall physical and mental component summary measures.
Baseline scores entered in the regression models.
|
at baseline and 3, 6, and 12 months.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Peter G. Rose, MD, Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CASE8808 (Other Identifier: Case Comprehensive Cancer Center)
- P30CA043703 (U.S. NIH Grant/Contract)
- CASE-8808-CC516 (Other Identifier: Cancer Center IRB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometrial Cancer
-
Ain Shams Maternity HospitalNot yet recruitingTreatment Endometrial Cancer
-
Radboud University Medical CenterMaastricht University Medical Center; Erasmus Medical Center; Catharina Ziekenhuis... and other collaboratorsRecruitingEndometrial Cancer Recurrent | Endometrial Cancer Stage III | Endometrial Cancer Stage IVNetherlands
-
Assistance Publique - Hôpitaux de ParisUniversité Montpellier; Ecole d'econmie de Paris (PSE)-Hospinnomics; Université...CompletedEndometrial Cancer Stage I | Endometrial Cancer Stage IIFrance
-
Mayo ClinicRecruitingEndometrial Carcinoma | Stage III Endometrial Cancer | Stage IV Endometrial Cancer | Endometrial High Grade Endometrioid Adenocarcinoma | Stage II Endometrial CancerUnited States
-
Batman Training and Research HospitalEskisehir Osmangazi UniversityCompletedGynecologic Cancer | Endometrial Cancer Stage
-
Novartis PharmaceuticalsCompletedAdvanced Endometrial CancerBelgium, France, Italy, Canada, Spain, Australia, Germany, United States, Japan, Brazil, Singapore, Russian Federation, Poland
-
Eli Lilly and CompanyGynecologic Oncology GroupCompletedNeoplasms | Urogenital Neoplasms | Neoplasms by Site | Uterine Neoplasms | Genital Neoplasms, Female | Endometrial Neoplasms | Endometrial Cancer | Endometrium Cancer | Cancer of Endometrium | Cancer of the Endometrium | Neoplasms, EndometrialUnited States
-
Rambam Health Care CampusCompletedSerous Papillary Endometrial CancerIsrael
-
University of OklahomaCompletedEndometrial Cancer | Papillary Serous | Clear Cell Endometrial CancerUnited States
-
University of Southern DenmarkDanish Cancer Society; Region of Southern DenmarkRecruitingEmpowerment, Cervical Cancer, Endometrial Cancer, Follow-up, Nurse-led, PROMDenmark
Clinical Trials on behavioral dietary intervention
-
Brown UniversityNational Cancer Institute (NCI)UnknownUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Brown UniversityNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedBreast CarcinomaUnited States
-
Rush University Medical CenterUniversity of Chicago; National Institute on Aging (NIA); Advocate Hospital SystemActive, not recruitingStroke | Dementia | Alzheimer Disease | Dementia, Vascular | Cognitive DeclineUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingRecurrent Bladder Carcinoma | Stage 0a Bladder Cancer AJCC v8 | Recurrent Non-Muscle Invasive Bladder Carcinoma | Non-Muscle Invasive Bladder Carcinoma | Stage 1 Bladder Cancer AJCC v8United States
-
Case Comprehensive Cancer CenterCompletedEndometrial Cancer | Weight ChangesUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedProstate CancerUnited States
-
Josephine Ford Cancer CenterNational Cancer Institute (NCI)UnknownUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Virginia Polytechnic Institute and State UniversityNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)CompletedStage 0 Breast Cancer | Cancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States